MedEx answers any queries you might have regarding Temodal-100 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Indications for use
Initial glioblastoma multiforme in the complex therapy;
Recurrent phase of glioma of malignant type;
Progressive anaplastic astrocytoma at the end of classical treatment regimens;
Malignant melanoma with metastases common character (Temodal is a first-line drug in this case)
Temodal is not recommended in case of hypersensitivity to temozolomide, dacarbazine, auxiliary components.
Do not use in the following conditions:
myelosuppressive conditions of the expressed type;
malignant glioma with recurrence or progression of the disease (children under 36 months);
initial multiform glioblastoma (children and adolescents);
malignant melanoma (children and adolescents),
intolerance to glucose, galactose, lactase deficiency.
Pregnancy and breast-feeding
Drugs based on temozolomide are absolutely contraindicated to pregnant women. Before you start treatment with Temodal , you should exclude the fact that you may be pregnant.
The drug is not recommended during breastfeeding. Breast-feeding is stopped in case of vital necessity of treatment with Temodal.
Method of reception
Temodal capsules are taken orally within one hour before meal. The pills should not be chewed or divided. You will be prescribed such dosages where you will use the minimum number of capsules. The pills are taken with water.
Combinatorial treatment with Temodal in case of glioblastoma multiforme with radiation therapy involves a daily dose of 0.075 g/m2. The course of therapy is 42 days. It is not recommended to reduce the dosage. If you have a poor tolerance of the drug may, you may have interruptions in the therapy.
Adjuvant therapy should begin no earlier than in a month after combinatorial treatment. It is carried out in 6 cycles in a strict sequence.
Treatment of the progressive form of malignant glioma, glioma of malignant nature in a recurrent form in case of multiform glioblastoma or anaplastic astrocytoma, treatment of malignant melanoma with metastases takes place according to this scheme:
– 0.2 g / m2 daily, 5 days, then there is a break of 23 days (if there is no chemotherapy);
– 0.15 g/m2 in the first cycle for 5 days, followed by a break of 23 days, the second cycle starts with a dosage of 0.2 g / m2 (after chemotherapy).
Dosages depend on the tests and the condition of a patient, the condition of which is monitored by an attending physician.
The maximum course of therapy is 2 years. If there is a progression of pathology in the background of treatment cycles, the therapy should be interrupted.